CDKN2A and familial pancreatic carcinoma: Another phase I clinical study using a pooled mutant-KRAS peptide vaccine is ongoing in high-risk group for developing pancreatic cancer (familial pancreatic cancer relative or germline mutation carrier for pancreatic cancer susceptibility genes like BRCA2, p16/CDKN2A, ATM, PALB2) to evaluate safety and immunogenicity of the vaccine (NCT05013216).